A detailed history of American Portfolios Advisors transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 10,000 shares of STRO stock, worth $27,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Holding current value
$27,500
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$5.17 - $7.11 $51,700 - $71,100
10,000 New
10,000 $55.5 Million
Q1 2022

Mar 21, 2023

SELL
$7.78 - $15.31 $7,002 - $13,779
-900 Reduced 9.0%
9,100 $74.8 Million
Q4 2021

Mar 21, 2023

SELL
$14.25 - $23.53 $28,143 - $46,471
-1,975 Reduced 19.75%
8,025 $119 Million
Q3 2021

Mar 22, 2023

SELL
$16.88 - $22.38 $33,338 - $44,200
-1,975 Reduced 19.75%
8,025 $152 Million
Q2 2021

Mar 22, 2023

SELL
$18.03 - $23.82 $35,609 - $47,044
-1,975 Reduced 19.75%
8,025 $149 Million
Q1 2021

Mar 22, 2023

SELL
$20.29 - $27.54 $47,681 - $64,719
-2,350 Reduced 23.5%
7,650 $174 Million
Q4 2020

Mar 22, 2023

SELL
$10.16 - $23.98 $26,416 - $62,348
-2,600 Reduced 26.0%
7,400 $161 Million
Q3 2020

Mar 22, 2023

SELL
$7.44 - $13.15 $11,346 - $20,053
-1,525 Reduced 15.25%
8,475 $85.2 Million
Q2 2020

Mar 24, 2023

BUY
$7.24 - $11.05 $18,100 - $27,625
2,500 Added 71.94%
5,975 $46.4 Million
Q1 2020

Mar 24, 2023

SELL
$6.19 - $12.16 $40,389 - $79,344
-6,525 Reduced 65.25%
3,475 $35.4 Million
Q4 2019

Mar 24, 2023

SELL
$8.15 - $11.39 $63,773 - $89,126
-7,825 Reduced 78.25%
2,175 $23.9 Million
Q3 2019

Mar 24, 2023

SELL
$7.91 - $11.76 $74,354 - $110,544
-9,400 Reduced 94.0%
600 $5.45 Million

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $143M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.